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Abstract
Heparanase (HPSE) and fibroblast growth factor-2
(FGF2) are critical regulators of melanoma angio-
genesis and metastasis. Elevated HPSE expression
contributes tomelanomaprogression; however, further
augmentation of HPSE presence can inhibit tumori-
genicity. HPSE enzymatically cleaves heparan sulfate
glycosaminoglycan chains (HS) from proteoglycans.
HS act as both low-affinity FGF2 receptors and co-
receptors in the formation of high-affinity FGF2 recep-
tors. We have investigated HPSE’s ability to modulate
FGF2 activity through HS remodeling. Extensive HPSE
degradation of human metastatic melanoma cells
(70W) inhibited FGF2 binding. Unexpectedly, treatment
of 70W cells with low HPSE concentrations enhanced
FGF2 binding. In addition, HPSE-unexposed cells did
not phosphorylate extracellular signal–related kinase
(ERK) or focal adhesion kinase (FAK) in response to
FGF2. Conversely, in cells treated with HPSE, FGF2
stimulated ERK and FAK phosphorylation. Secondly,
the presence of soluble HPSE-degraded HS enhanced
FGF2 binding and ERK phosphorylation at low HS
concentrations. Higher concentrations of soluble HS
inhibited FGF2 binding, but FGF2 signaling through
ERK remained enhanced. Soluble HS were unable to
support FGF2-stimulated FAK phosphorylation irre-
spective of HPSE treatment. Finally, cell exposure to
HPSE or to HPSE-degraded HS modulated FGF2-
induced angiogenesis in melanoma. In conclusion,
these effects suggest relevant mechanisms for the
HPSE modulation of melanoma growth factor respon-
siveness and tumorigenicity.
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Introduction
How cancer cells respond differentially to growth factors
plays a major role in cancer progression. One family of mol-
ecules, heparan sulfate proteoglycans (HSPG)1, is present
both on the cell surface and in the surrounding extracellular
matrix (ECM) and plays a major role in cellular behavior,
leading to tumor growth and metastasis [1]. Much of HSPG
biologic activity is mediated by their heparan sulfate glycos-
aminoglycan chains (HS) through the binding of a wide variety
of growth factors, growth factor receptors, and adhesion mole-
cules [2]. In addition, quantitative and qualitative changes
occur in HS expressed by metastatic versus normal cells [2].
These include variations in chain sequence, sulfation, and
length [2,3], leading to alterations in the ability of HS tomodulate
biologic activity [4].
HS sequence and length are regulators of fibroblast growth
factor-2 (FGF2) activity, an important mediator of melanoma
angiogenesis and progression [5]. HS bind to both FGF2 and
FGF receptors (FGFR) [6]. Cell surface HSPG are low-affinity
receptors for FGF2 through their HS. HSPG also form a ternary
complex with FGF2 and their tyrosine kinase–containing
FGFR, resulting in the formation of high-affinity binding sites
[7,8]. Finally, soluble HS or the highly sulfated form of HS, hep-
arin, can mediate the binding of FGF2 to FGFR, bypassing the
need for cell surface HSPG [6].
FGF2 binding phosphorylates both extracellular signal–
related kinase (ERK) and focal adhesion kinase (FAK), although
not necessarily through the same signaling pathway [9,10].
Signal transduction pathways that include ERK are important
regulators of cell growth and invasion and are altered during
melanoma progression to metastatic phenotype [11,12]. ERK is
also phosphorylated in response to a wide variety of extracellular
signals, including adhesion molecules and growth factors,
whereas FAK is activated during integrin binding and mediates
signal transduction for biologic functions such as adhesion, mi-
gration, and survival [13]. For example, pathways that stimulate
ERK phosphorylation in melanoma cells may then affect the
production of angiogenic factors. ERK and FAK can also partici-
pate in shared signaling pathways (i.e., when integrin-induced
FAK phosphorylation stimulates ERK signaling) [14]. However,
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depending on the cellular system, ERK may be upstream of
FAK [15], FAK may act as a potentiator of ERK signaling [16],
or ERK may be independent of FAK activation [17,18].
HS remodeling by bacterial heparitinases modulates
FGF2 binding, signaling, and subsequent activity. Depending
on cell type and method of removal, degradation of cell
surface HS can prevent the formation of high-affinity ternary
complexes [19]. Free HS released by heparitinase can then
act as either promoters or inhibitors of growth factor actions
[20]. Conversely, FGF2 binding and activity can be affected to
differing extents, particularly as ligand binding to a small
number of receptors can stimulate a biologic response [21].
Heparanase (HPSE) has differential effects on growth factor
activity, depending on the HS sequence it cleaves and the
HS tissue origin. For example, soluble HS cleaved by bacte-
rial heparitinase I (Hep I) promote FGF2 activity, whereas
heparitinase III (Hep III)–cleaved HS do not [22].
Mammalian HPSE is an endoglycosidase (endo-b-D-glucu-
ronidase), which degrades HS in a sequence-dependent
manner [23]. It produces HS fragments larger than those
produced by bacterial Hep I or Hep III enzymes; thus far, it
has not been as well studied for its effects on growth factor
activity. There are indications that HPSE activity is important
in remodeling HS and in subsequent modification of growth
factor activity (e.g., HPSE treatment of soluble syndecan-1,
an important HSPG implicated in tumor biology, converts
syndecan-1 from an inhibitor of FGF2 activity to a promoter of
FGF2-stimulated mitogenesis) [24]. Early studies found that
HPSE can increase the cellular availability of FGF2 by releas-
ing sequestered FGF2 from the ECM into a bioactive form [2].
Of relevance, HPSE protein expression is upregulated in a
wide variety of cancers [23], including malignant melanoma
[25]. Overexpression of HPSE in transfected lymphoma [26]
or melanoma cells [27] has been shown to augment tumor
metastasis and angiogenesis. Likewise, inhibition of HPSE
expression with antisense or siRNA techniques resulted in a
significant decrease in melanoma metastatic phenotype
[27,28]. However, it has been shown in a glioma model sys-
tem that moderate levels of HPSE promoted tumor growth
and invasion, whereas higher levels did not, indicating con-
centration dependence for its activity [29].
The present study focuses on HPSE’s ability to both
enhance and inhibit FGF2 binding and activity in an HPSE
concentration-dependent manner. We studied HPSE-
generated remodeling of both cell surface and soluble HS
by determining how: 1) HPSE cleavage of cell surface HSPG
modifies FGF2 binding and signaling; 2) HS produced by
HPSE degradation modulate FGF2 binding and signal trans-
duction; and 3) FGF2-induced angiogenesis is enhanced
by HPSE and HPSE-generated HS at the same concentra-
tions that augment FGF2 binding and signaling.
Materials and Methods
Tissue Culture and Enzymatic Treatments
Human 70W melanoma cells, which possess high meta-
static abilities compared to MeWo parental counterparts [30],
were maintained as subconfluent monolayer cultures in Dul-
becco’s modified Eagle’s F-12 medium (DME/F-12) supple-
mented with 10% (vol/vol) fetal bovine serum, as previously
described [30]. Cells were washed thrice in DME/F-12 con-
taining 0.1% bovine serum albumin (BSA) and penicillin/
streptomycin, then incubated with indicated concentrations
(0–5 mg/ml) of recombinant HPSE in 10mMHEPES-buffered
DME/F-12 (pH 6.8) containing 0.1% BSA and penicillin/
streptomycin, or with Hep III in 10 mM HEPES-buffered
DME/F-12 (pH 7.4) containing 0.1% BSA and penicillin/
streptomycin for 18 hours at 37jC. For Hep III– treated cells,
an additional aliquot of enzyme was added on the last hour
of incubation to counter possible enzyme inactivation. The
above conditions were chosen for different enzyme optimum
values for pH and time while maintaining experimental con-
ditions as close as possible. Cells were washed thrice with
DME/F-12 containing 0.1% BSA and penicillin/streptomycin
before initiating the experiments.
HPSE Isolation and Activity
Recombinant human HPSE was purified as previously
described [30,31]. Briefly, Sf9 insect cells, transfected with
baculovirus transfer vectors containing HPSE subunits, were
grown in SF900II serum-free medium (Gibco BRL, Grand
Island, NY) for high-titer stocks. Tni cells cultured in suspen-
sion using ExCell405 serum-free medium (JRH Bioscience,
Lenexa, KS) were infected with high-titer stock for 48 hours,
and cells were subsequently removed by centrifugation. The
supernatant was then tested for HPSE activity, filtered
through a 0.45-mm filter, and loaded on a HiTrap heparin
column (Amersham Biosciences, Piscataway, NJ). The
column was subsequently washed in Tris-buffered saline
(TBS) then eluted using a 100-ml gradient of 0.15 to 1.0 M
NaCl in 25 mM Tris–HCl (pH 7.5). Collected fractions (1 ml)
were screened for HPSE activity (Heparan Degrading En-
zyme Assay Kit; Takara Mirus, Madison, WI) [30]. HPSE
eluted at 0.67 M NaCl, as expected [31].
Immunofluorescent Staining
70W cells were plated at 10% density in Lab-TekII cham-
berslides (Nalge Nunc International, Rochester, NY) in DME/
F-12–10% (vol/vol) fetal bovine serum and allowed to at-
tach and grow for 24 hours. Cells were treated with HPSE or
Hep III as described above, and cell surface HS were de-
tected using an anti–heparan sulfate monoclonal antibody
(mAb) 10E4 (1:50 dilution; Seikagaku America, Falmouth,
MA) followed by incubation with AlexaFluor 488 goat–anti-
mouse IgM (1:400 dilution; Molecular Probes, Eugene, OR).
Digital images were produced using an Axioplan fluorescent
microscope (Carl Zeiss Microimaging, Thornwood, NY) with
Microfire digital camera (Optronics, Goleta, CA) and Picture-
frame imaging program (Optronics) using identical conditions
for all photographs.
Cellular HS Labeling and Degradation
70W cells were plated in 24-well tissue culture plates
for 24 hours to allow cell attachment. Cells were labeled with
20 mCi/ml [35S]sulfate (Amersham Biosciences) for 24 hours,
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washed with DME/F-12 containing 0.1% BSA and penicillin/
streptomycin, and treated with HPSE or Hep III, as described
above. The medium was sampled at 0-hour time point to
assure adequate washing. Conditioned medium was col-
lected at 18 hours, added to Ultimate Gold (PerkinElmer Life
and Analytical Sciences, Boston, MA) scintillation cocktail,
and counted in a liquid scintillation analyzer (PerkinElmer
Life and Analytical Sciences). Cells were solubilized, and
associated [35S]sulfate was counted. Cell-associated and
released counts were added for total [35S]sulfate.
HS Degradation and Analysis
To degrade heparin or HS (bovine kidney HS; Sigma-
Aldrich, St. Louis, MO), 250 ng of HS was incubated for
16 hours at 37jC with either HPSE (10 mg/ml) in 20 mM so-
dium acetate (pH 5.0), or Hep III (0.1 mg/ml) in 10 mM Tris–
HCl (pH 7.4), 150 mM NaCl, and 4 mM CaCl2 (final volume,
70 ml). Hep III–mediated degradation could be achieved in
two 30-minute incubations; however, to mimic conditions for
HPSE, a longer incubation time was maintained. Following
digestion, enzymes were inactivated for 10 minutes at 100jC.
Mock digestionswere performedwithout enzymes as controls.
Additional controls were performed using these enzymes
without the presence of heparin or HS (data not shown).
HPSE-degraded HS used in binding and signaling experi-
ments was analyzed by separating HS and heparin on a
Criterion 4–20% TBE gel (Bio-Rad Laboratories, Hercules,
CA) for 20 minutes at 60 mA. Bands were visualized with
Alcian blue 8GX (Sigma-Aldrich), followed by silver staining
(Pierce Endogen, Rockford, IL) [32]. Densitometric analyses
were performed using a Versadoc imaging system (Bio-Rad
Laboratories) to determine profiles’ leading edge.
HPSE activity was determined by the degradation of a
high-molecular-weight fraction of FITC-HS, which was pre-
pared by employing the same HS used for binding and signal
transduction experiments. FITC-HS was incubated for 0 to
24 hours with HPSE, as per above. After HPSE inactivation,
the pH was adjusted using 0.5 M Tris (pH 8.0), and FITC-HS
was analyzed using high-speed TSK gel permeation column
chromatography [high-performance liquid chromatography
(HPLC)], as previously described [30].
FGF2 Binding Assays
A widely accepted [125I]FGF2 binding assay was used in
our analyses [20,22]. Cells were plated in 24-well gelatin-
coated tissue culture plates for 24 to 48 hours to allow cell
adhesion. Cells were treated with HPSE or Hep III, as de-
scribed above. Cells were washed thrice with binding buffer
[HEPES-buffered DME/F-12 (pH 7.4) containing 0.2% BSA]
at 4jC, and cells were subsequently assayed for [125I]FGF2
(Amersham Biosciences) binding, as previously reported
[20,33]. Briefly, cells were incubated for 3 hours with 200 pM
[125I]FGF2 in binding buffer at 4jC. They were then washed
thrice with 20 mM HEPES (pH 7.4) containing 150 mM NaCl
and 0.2% BSA at 4jC. Low-affinity HSPG binding sites were
detected by two collected 1-ml washes of 20 mM HEPES
(pH 7.4) containing 2 M NaCl and 0.2% BSA at 4jC. High-
affinity FGFR complex binding sites were detected by two
collected 1-ml washes of 20 mM sodium acetate (pH 4.0)
containing 2MNaCl and 0.2%BSA at 4jC. Collected washes
were counted in a Clinigamma counter (LKB Wallac, Gai-
thersburg, MD). For [125I]FGF2 binding assays in the pres-
ence of soluble HS, [125I]FGF2 and HS (0–1000 ng/ml) were
added together, and assays were continued as described
above. Control experiments were performed with unlabeled
FGF2 to determine nonspecific binding. Results were
reported as the relative binding of experimental condition
compared to untreated or mock-treated controls. Signifi-
cant differences in [125I]FGF2 binding were determined by
Student’s t test.
Western Blot Analysis of ERK and FAK Phosphorylation
For signal transduction studies, cells were plated in
12-well tissue culturewells for 48 hours to allow cell adhesion.
HPSE treatments of cell surface HS were performed as
described above. Cells were exposed to 10 ng/ml FGF2 for
10 minutes at 37jC. Where indicated, FGF2 was added
together with 0 to 1000 ng/ml HS. Following stimulation, the
medium was aspirated from cells, and 100 ml of lysis buffer
[20 mM Tris–HCl (pH 7.4) containing 1% sodium dodecyl
sulfate, 1 mM phenylmethylsulphonyl fluoride, 0.1 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride, 0.1 mM sodium molyb-
date, 1mMsodiumorthovanadate, and 5 mg/ml aprotinin] was
added at 4jC. Lysed cells were scraped from the dish and put
through three to six cycles of freezing in liquid nitrogen and
heating up to 100jC for 5 minutes.
Samples for Western blot analysis were incubated at
100jC for 5 min with Laemmli sample buffer and separated
on a 4–15% Criterion gel (Tris–HCl; Bio-Rad Laboratories).
Proteins were transferred to polyvinylidene difluoride mem-
brane (Pierce Endogen). Membranes were incubated in a
blocking reagent [3% (wt/vol) nonfat dry milk and 0.5% (wt/
vol) BSA in TBS] for 2 hours, and then a buffer was added for
an additional 30 minutes. Membranes were then incubated
for 16 hours in blocking reagent with one of the following
primary antibodies: anti-phosphorylated FAK (tyrosine 397)
polyclonal antibody (Biosource International, Camarillo, CA),
anti-FAK polyclonal antibody, anti-ERK mAb, or anti-phos-
phorylated ERK mAb (Cell Signaling Technology, Beverly,
MA). Membranes were washed for 1 hour with six to eight
changes of TBS containing 0.5% IGE-PAL (CA-630; Sigma-
Aldrich) and incubated with horseradish peroxidase–
anti-mouse or anti-rabbit IgG (1:10,000 dilution; Accurate
Chemical and Scientific Co., Westbury, NY). Membranes
were then washed and developed using the Supersignal west
femto maximum sensitivity substrate (Pierce Endogen). La-
beling was detected and quantified using a Versadoc imaging
system (Bio-Rad Laboratories).
Angiogenic Assays
Where indicated, cells were pretreated with HPSE or
mock-treated, as per above. 70W cells were then released
with a brief trypsin treatment and added to 1 mg/ml soybean
trypsin inhibitor in DME/F-12 containing 0.1% BSA, washed
twice in DME/F-12, and resuspended at 1  107 cells/ml
in 50% reduced growth factor Matrigel (Becton Dickinson,
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Labware, Bedford, MA) in DME/F-12 at 4jC. HPSE, HS
fragments, and FGF2 (10 ng/ml) were added accordingly.
With the use of a 25-gauge needle, cells (2  106) were in-
jected to the left and right abdominal subcutaneous tissues
of female nude mice (Harlan Teklan, Madison, WI). Mice
were sacrificed on day 10, tumors were excised, fixed in
10% formalin, embedded in paraffin, and cut to 7-mm sec-
tions, which were stained with hematoxylin and eosin (H&E).
Blood vessel density was assessed by examining three inde-
pendent areas in each of three independent sections. Sig-
nificant differences in angiogenesis were determined by
Student’s t test and 90% confidence intervals, using Micro-
soft Excel (Microsoft Corporation, Redmond, WA).
Results
HPSE Action Remodels Cell Surface HS
The extent of HS remodeling on 70W by HPSE was
assessed both by immunofluorescence and by the release
of metabolically labeled HS into the culture medium. No
detectable reduction in HS expression levels was seen by
immunofluorescent labeling of HS after treating cells with
5 ng/ml HPSE versus no HPSE (Figure 1, A and B). When
cells were treated with higher HPSE concentrations (50–
500 ng/ml), a decrease in cell surface HS expression was
observed (Figure 1, C and D). HS expression also dimin-
ished when cells were exposed to increasing Hep III con-
centrations (Figure 1, E and H ). Comparable results were
obtained when cells, whose HS were metabolically labeled
with [35S]sulfate, were treated with HPSE and then radio-
labeled HS in the culture medium were monitored. Lower
HPSE concentrations (50 ng/ml and below) did not result in
significant HS in the medium (Figure 1I ). However, HPSE
effectively released HS at higher concentrations (100–
2500 ng/ml). Hep III release of labeled HSwas linear between
5 and 2500 ng/ml Hep III (Figure 1I ). Although Hep III cleaves
HS into smaller fragments, the degradation was not as
complete, possibly due to the reincorporation of released
HS into the cell.
HPSE Action Modulates FGF2 Binding
The integrity of HS on HSPG influences the binding of
heparin-binding growth factors. To determine whether HPSE
remodeling of HS affected FGF2 binding, 70W human mel-
anoma cells were degraded with HPSE (0–2500 ng/ml) and
assayed for FGF2 binding to low-affinity (HS) and high-
affinity (FGFR ternary complex) sites [20,22]. Inhibition of
low-affinity sites was detected at 50 ng/ml HPSE (24% in-
hibition; P < .005) and maximal inhibition (59% inhibition;
P < .005) was observed using 2.5 mg/ml HPSE (Figure 2A). At
the highest HPSE concentration (2.5 mg/ml), high-affinity
binding was inhibited by 48% (P < .005); thus, HPSE cleaved
sufficient cell surface HS to inhibit high-affinity FGF2 bind-
ing (Figure 2A). Notably, HPSE concentrations that did not
inhibit binding to low-affinity sites (5 ng/ml) enhanced FGF2
high-affinity binding by 157% (P < .01) compared to non–
HPSE-treated cells (Figure 2A).
Either the extent of HS degradation by enzymatic degra-
dation or differences in sequence cleavage could affect FGF2
binding. Therefore, 70W cells were treated with Hep III, a
bacterial exoglycosidase that extensively cleaves HS at sites
Figure 1. HPSE and Hep III degradation of cell surface HS (A–H). Human
70W melanoma cells, plated in chamber slides, were treated with (A) 0 ng/ml
HPSE, (B) 5 ng/ml HPSE, (C) 50 ng/ml HPSE, (D) 500 ng/ml HPSE, or (E)
0 ng/ml Hep III, (F) 5 ng/ml Hep III, (G) 50 ng/ml Hep III, and (H) 500 ng/ml
Hep III. Cells were then fixed and immunostained for HS. All images were
produced at identical conditions using an Axioplan fluorescent microscope
with Microfire digital camera and Pictureframe imaging program (see Ma-
terials and Methods section for details). Images are representative of two
independent experiments performed in duplicate. (I). Alternatively, 70W cells
were metabolically labeled for 24 hours with 20 Ci/ml [35S]sulfate, washed
to remove free sulfate, and incubated for 16 hours with indicated concen-
trations of HPSE (n) or Hep III (E). Conditioned medium and cell-associated
[35S]sulfate were counted in a liquid scintillation counter and reported as
mean fraction of [35S]sulfate released into the medium compared to mean
total [35S]sulfate (see Materials and Methods section for details) from trip-
licate determinations (± standard deviations).
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differing from HPSE and known to inhibit FGF2 binding on
other cell types [19]. Low-affinity FGF2 binding to Hep III–
exposed 70W cells was maximally inhibited (77% inhibition;
P < .005) at 2.5 mg/ml enzymatic concentrations (Figure 2B).
Likewise, Hep III degradation inhibited high-affinity FGF2
binding with maximal inhibition at 2.5 mg/ml Hep III (52% in-
hibition; P < .005). However, unlike HPSE, Hep III treatment
did not significantly enhance FGF2 binding to high-affinity
sites (Figure 2B).
HPSE Regulates FGF2 Signal Transduction by Degrading
Cell Surface HS
To determine whether FGF2 signal transduction depends
on HPSE treatment of cell surface HSPG, we assessed
FGF2-stimulated phosphorylation of molecular components
known to be activated during FGF2 signaling. FAK and ERK
are phosphorylated by different mechanisms on FGF2 stim-
ulation [18,21,34]. 70W cells were exposed to FGF2 follow-
ing cellular treatment with increasing HPSE concentrations.
Untreated cells did not phosphorylate ERK in response to
FGF2 (Figure 3). However, ERK phosphorylation was in-
creased in FGF2-stimulated cells following 0.5 ng/ml HPSE
treatment. Exposure of cells to 5ng/mlHPSE further enhanced
FGF2-mediated ERK phosphorylation (Figure 3). Higher
HPSE concentrations (5000 ng/ml) eliminated FGF2 stimu-
lation of ERK phosphorylation (Figure 3). The higher HPSE
concentration (5000 ng/ml) was used because 500 ng/ml
HPSE reduced FGF2-stimulated ERK phosphorylation but
did not abolish FGF2 response (data not shown). Furthermore,
FGF2-stimulated FAK phosphorylation occurred only in 70W
cells after HPSE treatment (Figure 3). Although FGF2 did not
affect FAK phosphorylation in untreated cells, FGF2 stimu-
lated FAK phosphorylation in cells treated with 0.5 to 5 ng/ml
HPSE (Figure3).AswithERK,HSdegradationwith 5000ng/ml
HPSE did not support FGF2-stimulated FAK phosphorylation.
Furthermore, FGF2-mediated ERK and FAK phosphorylation
(Figure 3) occurred at HPSE concentrations that increased
FGF2 binding (Figure 2B).
HPSE-Degraded HS Modulates FGF2 Binding
Sulfation patterns of HS are cell type–specific, and these
patterns have been shown to influence both HPSE activity
and FGF2 binding [20]. To define HPSE enzymatic cleavage
of HS and heparin used for FGF2 binding and signaling, we
first analyzed HS and heparin fragments produced following
HPSE treatment. Heparin or HS were incubated with HPSE
for 16 hours, and initial assessment of degradation was de-
termined by gel electrophoresis. Because HS were a heter-
ogeneous mixture, they migrate as a broad band during gel
electrophoresis (Figure 4A). HPSE-mediated HS degrada-
tion resulted in a migration shift, indicating a reduction in HS
fragment size (Figure 4A). This shift was small as expected
because HPSE does not extensively cleave HS. As control,
HS were treated with Hep III, which results in much smaller
fragments as indicated by their increased mobility. As ex-
pected, HPSE and Hep III degradation of heparin resulted in
a shift in migration smaller than the one observed for HS
(Figure 4, A and B). The leading edge of HS and heparin
profiles was determined after gel densitometric analysis
Figure 2. FGF2 binding of HPSE-treated or Hep III – treated human 70W
melanoma cells. Cells were incubated for 16 hours with indicated concen-
trations of HPSE (A) or Hep III (B), washed to remove free HS, and incubated
for 3 hours with [125I]FGF2. Bound [125I]FGF2 was separately released from
low-affinity (.) and high-affinity (n) sites, and radioactivity was counted using
an LKB gamma counter. Binding is reported as the mean [125I]FGF2 bound to
experimental conditions relative to the mean [125I]FGF2 bound to untreated
cells from triplicate determinations (± standard deviations).
Figure 3. FGF2 signaling in HPSE-treated human 70W melanoma cells.
Cells treated with 0 to 5000 ng/ml HPSE for 16 hours were washed, stimu-
lated for 10 minutes with FGF2 (10 ng/ml), and lysed. Total cell lysates were
then analyzed by Western blot analysis for total and phosphorylated ERK and
FAK proteins (see Materials and Methods section for details). Results are
representative of three independent experiments.
600 Heparanase Modulates FGF2 Binding and Signaling Reiland et al.
Neoplasia . Vol. 8, No. 7, 2006
(Figure 4B) and demonstrated consistent shifts toward lower-
molecular-weight HS with HPSE treatment compared to
non–HPSE-degraded controls (P < .03). To further estimate
reaction completion, a time course of HPSE degradation of
high-molecular-weight HS was analyzed by HPLC. HS was
fluorescently labeled with FITC, and then column chromatog-
raphy was used to isolate the high-molecular-weight fraction.
This was subsequently degraded with HPSE for varying
times, and the extent of degradation was assessed using
HPLC. A 4-hour HPSE treatment degraded 64% of initial HS
(Table 1), as demonstrated by the profile shift to the right
when compared to the non–HPSE-treated HS profile. How-
ever, retention time did not show a large shift, indicating that
degradation at 4 hours was not complete (Table 1). Con-
versely, at 16-hour HPSE incubation, both profiles (84%
degraded HS) and retention time shifts of FITC HS were
maximal, indicating reaction completion (Table 1).
We then assessed FGF2 binding in the presence of
heparin or bovine kidney HS degraded with or without HPSE.
Figure 5 shows that both HPSE-degradedHS fragments from
heparin (Figure 5,A andB) and bovine kidneyHS (Figure 5,C
and D) inhibited FGF2 low-affinity binding to 70W melanoma
cells at high (> 10 ng/ml) concentrations. Inhibition of low-
affinity binding was similar with HPSE-degraded or intact
(nondegraded) heparin (Figure 5A) and HS (Figure 5C),
although HPSE-degraded heparin was slightly more effective
at inhibiting low-affinity binding at low concentrations than
intact heparin or HS preparations. Similarly, both HS and
heparin inhibited high-affinity FGF2 binding at high concen-
trations. HPSEdegradation of HS or heparin was not required
for this binding inhibition. This binding was enhanced by the
addition of low concentrations of HPSE-degraded HS or
heparin compared to control heparin (Figure 5B) or HS
(Figure 5D). Therefore, HPSE altered HS and heparin; thus,
there was an increased high-affinity FGF2 binding at HS
concentrations that did not affect low-affinity binding.
HPSE-Degraded HS Modulates FGF2 Signal Transduction
Because HS length and sulfation patterns contributing to
FGF2 signal transduction can differ from those required for
binding, we examined the ability of HPSE-degraded HS to
facilitate FGF2-stimulated ERK and FAK phosphorylation.
As observed above, FGF2 failed to stimulate ERK phos-
phorylation in untreated 70W cells (Figure 6, A and B); how-
ever, incubation of cells with HPSE-degraded HS recovered
FGF2-stimulated ERK phosphorylation (Figure 6A). Like-
wise, control HS enhanced FGF2-stimulated ERK phosphor-
ylation at all considered concentrations (1–1000 ng/ml;
Figure 6B). FGF2-stimulatedERKphosphorylationwas robust
by several criteria. First, treatment of cells with 1000 ng/ml
HPSE-degraded HS (Figure 6A) effectively promoted FGF2-
stimulated ERK phosphorylation despite the inhibition of
FGF2 binding (Figure 5, C and D). This is not completely
unexpected as FGF2 activity has been previously found to
bemore difficult to inhibit than FGF2 binding [35,36]. Second,
control HS promoted FGF2-stimulated ERK phosphoryla-
tion (Figure 6B), although it did not augment FGF2 binding
(Figure 5C). Finally, FAK was not phosphorylated in re-
sponse to FGF2 in control 70W cells (Figure 6, A and B) as
was also observed in the HPSE degradation curve (Figure 3).
The addition of intact or HPSE-degraded HS did not recover
FGF2-stimulated FAK phosphorylation (Figure 6, A and B),
unlike the one detected in response to FGF2 in HPSE-
exposed cells (Figure 3).
HPSE and HPSE-Degraded HS Modulate FGF2-Induced
Angiogenesis
To determine whether degradation of cell surface HS
modifies tumor-induced angiogenesis, 70W cells were ex-
posed to increasing HPSE concentrations and injected sub-
cutaneously into athymic nude mice with FGF2 and HPSE.
Tumors were excised after 10 days and examined for blood
Table 1. HPLC Analysis of HS Digested by HPSE.
HS Digestion Time (hr) Retention Time (min) % Digested HS*
0 13.5 0
4 13.9 64
8 16.2 78
16 19.1 84
24 19.2 88
*The percentage of digested HS is the amount of HS HPLC profiles shifted
out of nontreated control profiles divided by the total HS present.
Figure 4. HPSE degrades HS and heparin. To assess HPSE-produced
fragments, HS (lanes 1–3) or heparin (lanes 4–6) was incubated for 16 hours
at 37C with either buffer alone (lanes 1 and 4), 10 g/ml HPSE (lanes 2 and
5), or 100 g/ml Hep III (lanes 3 and 6). HS and heparin were then separated
on a 4% to 20% TBE gel, and bands were visualized using Alcian blue dye
followed by silver staining (A). Densitometric analysis of the above gel
electrophoresis used a Versadoc imaging system (B). Migration is reported as
the relative front (rf) of the leading edge of profiles. Means and standard
deviations were determined from triplicate HS profiles. Significant differences
were assessed by Student’s t test (*P < .03, **P < .005).
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vessel formation. FGF2 enhanced melanoma blood vessel
formation by 2.3- to 3.6-fold (Figure 7). Treatment of mela-
noma cells with 10 ng/ml HPSE enhanced FGF2-induced
angiogenesis compared to FGF2 with no HPSE (P < .05;
Figure 7). Higher HPSE concentrations (1000 ng/ml) did
not increase FGF2-induced angiogenesis above controls
(FGF2, no HPSE). Treatment of FGF2-stimulated 70W cells
with 10 ng/ml HPSE resulted in augmented angiogenesis
compared to either no HPSE (P < .05) or cells treated with
1000 ng/ml HPSE (P < .005).
To define whether HPSE-degraded HS enhanced
FGF2-induced angiogenesis, melanoma cells treated with
HPSE-degraded HS, or mock-degraded intact HS, were
subcutaneously injected into athymic nude mice in the pres-
ence/absence of FGF2. FGF2 did not stimulate additional
angiogenesis above basal levels in melanoma tumors in-
jected without HS (Figure 8). This may be due to higher
basal levels of angiogenesis in these experiments compared
to ones without enzyme pretreatment (Figure 7). This is
possibly due to the conditions used for enzyme pretreatment.
Melanoma tumors treated with HPSE-degraded HS and
FGF2 had a significant increase in blood vessel density
compared to either no FGF2 (P < .005) or FGF2 but no HS
treatments (P < .03). Furthermore, the addition of intact HS
with FGF2 did not result in augmented angiogenesis above
basal levels.
Discussion
We report first-time evidence that HPSE alters metastatic
melanoma cell responsiveness to FGF2, including FGF2
binding, signaling, and FGF2-induced angiogenesis. This
provides a mechanism by which metastatic melanoma cells
can becomemore responsive to FGF2, a growth factor that is
important in melanoma progression. We have shown that
HPSE degradation of cell surface HS can both augment and
inhibit FGF2 activity, depending on the HPSE concentrations
used to remodel cell surface HS. We have demonstrated a
specificity of HPSE-modulated FGF2 increase in binding
and signaling because, when we exposed cells to Hep III, a
bacterial endoglycosidase, we observed a dose-dependent
inhibition of FGF binding and signaling; however, there was
no detectable increase. We also found that HPSE degrada-
tion of soluble heparin or HS produces fragments that either
potentiate or inhibit melanoma cell FGF2 binding and signal-
ing in an HS concentration-dependent manner. In addition,
our results demonstrate that FGF2-mediated signaling path-
ways are differentially affected depending on whether
cleaved HS are: 1) attached to cell surface HSPG or 2) in
soluble form. Although we found that HPSE is able to stimu-
late FGF2-mediated angiogenesis, high levels of HPSE,
which cause extensive HS degradation, are unable to sup-
port FGF2-mediated angiogenesis. Finally, we found that
HPSE-produced HS fragments are able to promote FGF2-
Figure 5. HPSE degradation of heparin or HS produces fragments that modulate FGF2 binding. Human 70W melanoma cells were incubated with [125I]FGF2 and
with indicated concentrations of heparin (A and B) or HS (C and D), which was predegraded with HPSE (n) or was mock-degraded (.). Samples were then
assayed for [125I]FGF2 binding to low-affinity (A and C) or high-affinity (B and D) sites. Binding is reported as the mean [125I]FGF2 bound with experimental
conditions relative to the mean [125I]FGF2 bound to untreated control cells from triplicate determinations (± standard deviations).
602 Heparanase Modulates FGF2 Binding and Signaling Reiland et al.
Neoplasia . Vol. 8, No. 7, 2006
stimulated tumor angiogenesis in the complete absence of
HPSE. Altogether, these results provide a relevant mecha-
nism to elucidate how HPSE regulates tumor angiogenesis.
The high-affinity ternary complex includes FGF2 and HS
as well as FGFR, which initiates signal transduction through
its tyrosine kinase domain [37]. Structural analysis indicates
that HS interacts with both FGF and FGFR in forming the
high-affinity ternary complex [38,39]. However, HS require-
ments for binding and signaling are not equivalent [40].
Native HS on untreated 70W cells does not support FGF2-
stimulated signaling, although it sustains binding. However,
HPSE can modify cellular HS to support FGF2-stimulated
signaling, potentially through modifying HS structures to alter
interactions with either FGF2 or FGFR, or both. HS inter-
actions can promote FGF2–FGFR dimerization initiating
transphosphorylation of the receptor and signaling, as correct
stoichiometry is required for FGF2 signaling [37,41]. Alter-
natively, HS may affect additional signal pathways required
for efficient propagation of FGF2 signaling [6,42].
High-affinity FGF2 binding and signaling require HS
sequence-specific interactions. Depending on the extent of
HS degradation, HS sequences, which bind to either FGF2 or
FGFR, could be removed or cryptic sites could be revealed
[24,43]. HS are highly heterogeneous oligomers due to exten-
sive postsynthesis modification of the basic GlcUAb1,4GlcNAc
unit. HPSE cleaves HS within a specified minimum sequence
(–GlcNAc(6S)–GlcUA–GlcN(NS)–)3 but also requires ad-
ditional sulfation in the surrounding sequence [44]. Sites for
HPSE cleavage occur infrequently in HS from multiple
sources, producing long fragments capable of promoting
FGF2 activity. There may also be additional sites of cleavage
[45] that are suppressed in highly sulfated regions [44]. The
HPSE cleavage sequence in HS does not overlap with the
FGF2 HS binding site, which requires 2-O sulfation in the se-
quence HexA(2SO4)–GlcNSO3 for binding [46,47]. Highly
sulfated regions are more effective at FGF2 binding as mul-
tiple 2-O sulfation increases binding [48,49]. In addition, HS
binding to the FGFR requires 6-O sulfation, which is critical
for strengthening FGF–FGFR binding and promoting receptor
dimerization [40]. Conversely, Hep III produces HS fragments
that are rich in IdoUA(2S)a1,4GlcNSO3(±6S) disaccharides
[50], and HS degradation is significantly more extensive than
with HPSE, resulting in the production of shorter HS frag-
ments. Although highly sulfated HS with as few as four di-
saccharides units can bind to FGF2, longer oligomers are
required for effective formation of the FGF2–FGFR stoichi-
ometry required for subsequent signaling [51].
HPSE cleavage of HS can potentially change core protein
membrane localization, consequently altering their availabil-
ity to interact with FGFR or other signaling molecules. This
has been demonstrated with the HSPG syndecan-1 [52] and
glypican [53], whose localization in the plasma membrane is
affected by removing HS or by inhibiting HS interactions.
HPSE can release soluble HS from both cell surface and
ECMHSPGand therefore alter the composition of soluble HS
available to the cell. Previously, it has been shown that HPSE
degradation of ECM releases HS with FGF2 in a bioactive
form [23]. It has also been demonstrated that HS produced by
bacterial heparitinases promoted tumorigenesis, depending
on HS sequence specificity of the enzyme. We now demon-
strate that HPSE, a unique mammalian HS degradative
enzyme that is present during tumor progression and in
normal physiological events, produces HS, which potentiate
or inhibit FGF2 binding and signaling according to HS con-
centration and the signaling intermediate. In addition, these
HS also promote tumor angiogenesis. Potentiation of FGF2
binding is more pronounced with HPSE-degraded heparin,
possibly because the increased sulfation on heparin presents
more FGF2 or FGFR binding sites. Enhanced binding and
ERK signaling could result from soluble HS, which are more
efficient than endogenous HS in the formation of the ternary
FGFR complex. It is unexpected that shorter HS formed by
HPSE degradation enhance ternary complex formation,
whereas longer intact HS do not. Again, this suggests that
HPSE cleavage may reveal cryptic binding sites or changes
in HS concentration and length that influence the stoichiom-
etry of the ternary complex.
In the melanoma cells used in this study, FGF2-stimulated
FAK phosphorylation required HPSE remodeling of resident
HSPG, and soluble HS did not recover FAK phosphorylation
(Figures 2 and 4). FGF2 signaling involves cross-talk or
stimulation with other signal transduction pathways [54].
Figure 6. HPSE degradation of heparin or HS produces fragments that
modulate FGF2-stimulated Erk but not FAK phosphorylation. Cells were
incubated for 10 minutes with FGF2 (10 ng/ml) in the presence of indicated
concentrations of HS predegraded with HPSE (A) or mock-degraded (B).
Cells were lysed and total cell extracts were analyzed by Western blot
analysis for total/phosphorylated forms of ERK or FAK, respectively (see
Materials and Methods section for details). Results are representative of
three independent experiments.
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For example, FGF2 can increase FAK phosphorylation initi-
ated through integrins in an HS-dependent manner [21].
HPSE can activate integrins, which are known to phosphor-
ylate FAK [29]. Therefore, in our cells, FAKmay be sufficiently
downstream of FGF2 that it requires activation of additional
pathways for phosphorylation [9]. HSPG roles are of further
interest because reducing the number of HS attached to a
single core protein can inhibit the ability of HSPG to promote
cell adhesion and invasion [55]. This would subsequently
inhibit signaling dependent on these adhesive interactions.
We also found a modulation of tumor angiogenesis by
HPSE and HPSE-degraded HS. Angiogenesis is dependent
on multiple components that can be affected by HPSE. HS in
the ECM provide binding sites for angiogenic factors such as
FGF2 and vascular endothelial growth factor. Cell surface
HSPGacts as growth factor and adhesion receptors on tumor
cells and vascular endothelial cells. Modifying the HS may
affect tumorigenicity by modifying the responsiveness of
multiple receptors to the extracellular environment. In addi-
tion, HPSE releases HS from the ECM, which can alter
binding and signaling initiated through endothelial or tumor
HS binding cell surface receptors.
Finally, recent evidence suggests that, although HPSE
upregulation in glioma cells results in augmented tumor
aggressiveness, further elevation of HPSE inhibits tumorige-
nicity [29]. Our work not only extends this notion to metastatic
melanoma, suggesting that HPSE modulates tumor respon-
siveness in multiple systems, but also demonstrates that
these changes can be affected by HPSE-mediated HS
remodeling of the tumor cell surface and the ECM. Extensive
degradation of cell surfaceHS can interferewith growth factor
binding and internalization [2,3]. However, a modest degra-
dation of cell surface HS could modify the structure of HS,
resulting in either decreased or increased interactions de-
pending on the growth factor. Furthermore, HPSE degrada-
tion of HS could change the availability of FGF2 in the tumor
microenvironment by releasing FGF2 from the matrix and the
cell surface. In addition to modifying FGF2 action, HPSE
could alter signaling initiated by multiple heparin binding
growth factors, fine-tuning cellular response to changes in
its environment. Besides FGF2, melanoma cells respond to
heparin binding growth factors, such as pleiotrophin and
vascular endothelial growth factor, whose binding and sig-
naling are also influenced by available HS [56,57]. This in turn
can allow differing modifications of various biologic
responses, such as angiogenesis or metastasis, depending
on growth factors’ availability and the amount of HPSE pres-
ent. It will be of interest to determine HPSE effects on the
Figure 7. HPSE degradation of melanoma cell surface HS modulates FGF2-induced tumor angiogenesis. 70W cells were incubated for 16 hours with indicated
HPSE concentrations. Cells were then released, resuspended with Matrigel in the presence or absence of FGF2, and injected subcutaneously into athymic nude
mice (n = 10). Tumors were allowed to grow for 10 days, excised, and formalin-fixed, and sections were stained with H&E (A). Blood vessels were quantified using
nine fields each of three independent sections per tumor (B). Original magnification, 40. Bar, 25 m. Errors are reported at 90% confidence intervals.
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binding and signaling of these and other heparin binding
growth factors and their related receptors, thus amplifying
our knowledge of HPSE-based mechanisms of action.
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